|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||0.0004 - 0.0004|
|52-week range||0.0004 - 0.0570|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).
Shares of biotechnology company Biophytis surged 73% to $1.59 on Monday following the announcement of a partnership deal with French pharmaceutical firm Skyepharma. The collaboration is set to produce regulatory batches of Sarconeos, a potential treatment for severe Covid-19 cases, in preparation for submitting marketing authorization applications.